DE69432730D1 - Rekombinante Adenovirus-Vakzinen - Google Patents

Rekombinante Adenovirus-Vakzinen

Info

Publication number
DE69432730D1
DE69432730D1 DE69432730T DE69432730T DE69432730D1 DE 69432730 D1 DE69432730 D1 DE 69432730D1 DE 69432730 T DE69432730 T DE 69432730T DE 69432730 T DE69432730 T DE 69432730T DE 69432730 D1 DE69432730 D1 DE 69432730D1
Authority
DE
Germany
Prior art keywords
recombinant adenovirus
cell mediated
mediated immunity
warm blooded
blooded mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432730T
Other languages
English (en)
Other versions
DE69432730T2 (de
Inventor
Alan Robert Davis
Paul Porwen Hung
Michael David Lubeck
Robert James Natuk
Pranab Kumar Chanda
Shridhara Chikkatur Sha Murthy
Shaw-Guang Lin Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of DE69432730D1 publication Critical patent/DE69432730D1/de
Publication of DE69432730T2 publication Critical patent/DE69432730T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
DE69432730T 1993-08-11 1994-07-29 Rekombinante Adenovirus-Vakzinen Expired - Fee Related DE69432730T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10523293A 1993-08-11 1993-08-11
US105232 1993-08-11
US27628994A 1994-07-20 1994-07-20
US276289 1994-07-20

Publications (2)

Publication Number Publication Date
DE69432730D1 true DE69432730D1 (de) 2003-07-03
DE69432730T2 DE69432730T2 (de) 2004-03-25

Family

ID=26802374

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432730T Expired - Fee Related DE69432730T2 (de) 1993-08-11 1994-07-29 Rekombinante Adenovirus-Vakzinen

Country Status (17)

Country Link
EP (1) EP0638316B1 (de)
JP (1) JPH07145079A (de)
KR (1) KR100347220B1 (de)
AT (1) ATE241385T1 (de)
AU (2) AU6889194A (de)
BR (1) BR9403202A (de)
CA (1) CA2130202A1 (de)
DE (1) DE69432730T2 (de)
DK (1) DK0638316T3 (de)
ES (1) ES2196018T3 (de)
FI (1) FI113621B (de)
HK (1) HK1009934A1 (de)
HU (1) HUT69793A (de)
IL (1) IL110560A (de)
NZ (1) NZ264190A (de)
PT (1) PT638316E (de)
SG (1) SG43029A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
JP2001500738A (ja) * 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2003047617A2 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
BRPI0504782A (pt) 2005-11-01 2007-09-18 Fundacao Oswaldo Cruz adenovìrus recombinantes, processo de construção de adenovìrus recombinantes, composição de vacina contra toxoplasmose, e método de imunização contra infecções causadas pelo parasita t. gondii

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
WO1992006990A1 (en) * 1990-10-17 1992-04-30 The United States Of America, Represented By The Secretary, United States Department Of Commerce Molecular clones of hiv-1 and uses thereof
WO1992011028A1 (en) * 1990-12-19 1992-07-09 Epitope, Inc. Hiv reverse transcriptase vaccine
ES2201055T3 (es) * 1992-08-07 2004-03-16 Wyeth Vacunas de adenovirus recombinante.

Also Published As

Publication number Publication date
DK0638316T3 (da) 2003-09-22
HK1009934A1 (en) 1999-06-11
CA2130202A1 (en) 1995-02-12
ES2196018T3 (es) 2003-12-16
FI943626A0 (fi) 1994-08-04
DE69432730T2 (de) 2004-03-25
EP0638316A1 (de) 1995-02-15
SG43029A1 (en) 1997-10-17
JPH07145079A (ja) 1995-06-06
FI113621B (fi) 2004-05-31
HU9402309D0 (en) 1994-10-28
IL110560A (en) 1998-10-30
AU6889194A (en) 1995-02-23
FI943626A (fi) 1995-02-12
HUT69793A (en) 1995-09-28
BR9403202A (pt) 1995-04-11
IL110560A0 (en) 1994-11-11
KR100347220B1 (ko) 2003-02-26
ATE241385T1 (de) 2003-06-15
EP0638316B1 (de) 2003-05-28
PT638316E (pt) 2003-10-31
AU4850697A (en) 1998-03-26
NZ264190A (en) 1997-06-24
KR950005326A (ko) 1995-03-20

Similar Documents

Publication Publication Date Title
PT586076E (pt) Vacinas de adenovirus recombinantes
ATE245164T1 (de) Rekombinanter papillomavirus l1
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
GEP20084431B (en) Papilloma virus vaccine
DK0638316T3 (da) Rekombinante adenovirusvacciner
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
DE69433760D1 (de) Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält
DK43991A (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee